查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1212613

DPP-IV抑制剂的全球市场

DPP-IV Inhibitors
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 262 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

DPP-IV抑制剂的全球市场到2030年将达到132亿美元

在COVID-19后改变的商务环境中，2022年估算为115亿美元的DPP-IV抑制剂的全球市场到2030年将修正达到132亿美元的规模，在分析期间的2022年～2030年间预计将以1.8％的年复合成长率增长。

美国市场占是34亿美元，中国则将以年复合成长率1.7％成长。

美国的DPP-IV抑制剂市场在2022年估算为34亿美元。作为世界第2大经济大国的中国，在2022年～2030年间年复合成长率预计将为1.7％，到2030年达到24亿美元的市场规模。其他热门的地区市场有日本和加拿大，在分析期间的2022年～2030年间预计将各以1.6％和1.5％的速度成长。欧洲市场中，德国将以年复合成长率2％成长。

调查对像企业范例

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 全球其他地区

第4章 竞争

简介目录
Product Code: MCP-6466

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global DPP-IV Inhibitors Market to Reach $13.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for DPP-IV Inhibitors estimated at US$11.5 Billion in the year 2022, is projected to reach a revised size of US$13.2 Billion by 2030, growing at a CAGR of 1.8% over the period 2022-2030.

The U.S. Market is Estimated at $3.4 Billion, While China is Forecast to Grow at 1.7% CAGR

The DPP-IV Inhibitors market in the U.S. is estimated at US$3.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.6% and 1.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR.

Select Competitors (Total 16 Featured):

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
    • Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
    • Recent Market Activity
    • TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
    • Management of T2DM with DPP-4 Combination Therapy
    • FDA Approves Merck's First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy
    • DPP-IV Inhibitors - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
    • AstraZeneca Plc. (UK)
    • Boehringer Ingelheim GmbH (Germany)
    • Eli Lilly and Company (USA)
    • Merck & Co, Inc. (USA)
    • Mitsubishi Tanabe Pharma Corporation (Japan)
    • Novartis AG (Switzerland)
    • Takeda Pharmaceutical Company Limited (Japan)
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World DPP-IV Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 4: USA Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • CANADA
    • TABLE 5: Canada Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • JAPAN
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 6: Japan Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • CHINA
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 7: China Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • EUROPE
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 8: Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: Europe 8-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
  • FRANCE
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 10: France Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • GERMANY
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 11: Germany Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • ITALY
    • TABLE 12: Italy Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • UNITED KINGDOM
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 13: UK Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • REST OF EUROPE
    • TABLE 14: Rest of Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • ASIA-PACIFIC
    • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 15: Asia-Pacific Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • REST OF WORLD
    • TABLE 16: Rest of World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR

IV. COMPETITION